List of Excipients in Branded Drug ATTRUBY

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
BridgeBio Pharma Inc	ATTRUBY	acoramidis hydrochloride	82228-712	CELLULOSE, MICROCRYSTALLINE	2039-08-16
BridgeBio Pharma Inc	ATTRUBY	acoramidis hydrochloride	82228-712	CROSCARMELLOSE SODIUM	2039-08-16
BridgeBio Pharma Inc	ATTRUBY	acoramidis hydrochloride	82228-712	FERROSOFERRIC OXIDE	2039-08-16

ATTRUBY Excipient Strategy and Commercial Opportunities

Last updated: September 23, 2026

ATTRUBY, the brand name for acoramidis hydrochloride, is an FDA-approved oral stabilizer of transthyretin for adults with wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy. Its formulation uses a conventional immediate-release film-coated tablet with widely available excipients. The commercial opportunity is therefore concentrated in reliable high-volume supply, low-variability pharmaceutical-grade materials, coating-system performance, and generic-development support rather than in novel-excipient differentiation.

ATTRUBY was approved by the FDA on November 22, 2024. The labeled dose is 712 mg twice daily, delivered as two 356 mg tablets per dose.[1] This creates a four-tablet daily regimen and a substantial recurring demand for active pharmaceutical ingredient, compression excipients, film-coating materials, packaging, and manufacturing capacity.

What excipients are used in ATTRUBY tablets?

ATTRUBY uses a standard solid-oral formulation platform. The FDA prescribing information identifies the following inactive ingredients:[1]

Excipient	Likely formulation role	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	High-volume tablet excipient; supports direct compression
Croscarmellose sodium	Superdisintegrant	Supports rapid tablet breakup and release
Magnesium stearate	Lubricant	Controls ejection and tooling friction
Colloidal silicon dioxide	Glidant and flow aid	Improves powder flow and blend uniformity
Polyvinyl alcohol	Film-former	Supports tablet coating integrity
Talc	Coating aid and anti-tacking agent	Improves coating processability
Titanium dioxide	Opacifier and pigment	Provides white, opaque coating

The label does not identify a novel excipient, lipid-based delivery system, enteric system, osmotic system, modified-release matrix, or polymeric drug-delivery platform.[1]

What is the ATTRUBY dosage form?

ATTRUBY is a 356 mg film-coated tablet. The recommended regimen is two tablets orally twice daily, for a total daily dose of 1,424 mg acoramidis hydrochloride.[1]

The formulation has several commercial implications:

• Tablet count is high relative to once-daily cardiology products.
• Tablet size and mechanical strength are important because patients take four tablets each day.
• Blend uniformity is critical because the product contains a high drug load.
• Coating robustness matters for appearance, moisture protection, handling, and patient acceptability.
• The formulation is compatible with established high-speed tablet manufacturing and coating equipment.

How does the ATTRUBY excipient strategy compare with competing ATTR-CM drugs?

ATTRUBY competes primarily with tafamidis products, including VYNDAMAX and VYNDAQEL. Both product families use oral solid dosage forms, but the products differ in active ingredient, dosing, formulation, and commercial positioning.

Attribute	ATTRUBY	VYNDAMAX	VYNDAQEL
Active ingredient	Acoramidis hydrochloride	Tafamidis	Tafamidis meglumine
Indication	Wild-type or hereditary ATTR cardiomyopathy	Wild-type or hereditary ATTR cardiomyopathy	Wild-type or hereditary ATTR cardiomyopathy and hereditary ATTR polyneuropathy in applicable markets
Dosage form	Film-coated tablet	Soft capsule	Soft capsule
U.S. FDA approval	November 22, 2024	May 3, 2019	May 3, 2019
Typical U.S. dose	712 mg twice daily	80 mg once daily	80 mg tafamidis equivalent once daily for ATTR-CM
Daily unit burden	Four tablets	Four 20 mg capsules, or one 61 mg capsule depending on product	Four 20 mg capsules
Formulation platform	Conventional tablet	Capsule-based formulation	Capsule-based formulation

Tafamidis was the first major U.S. commercial product in ATTR cardiomyopathy. ATTRUBY enters a market with established diagnosis, specialist prescribing, payer review, and treatment guidelines. Its tablet platform may support supply-chain and manufacturing flexibility compared with soft-gel capsule products, although the four-tablet daily regimen remains a potential adherence issue.

What excipient supply opportunities exist for ATTRUBY?

The most attractive opportunities are in excipient supply contracts, dual sourcing, quality-by-design support, and generic replication. The formulation does not require a rare or technically complex excipient package.

Microcrystalline cellulose

Microcrystalline cellulose is likely to be the largest excipient by weight. Suppliers with pharmaceutical-grade direct-compression grades can compete on:

• Bulk density and particle-size distribution
• Compressibility
• Low variability between lots
• Low moisture and controlled water activity
• Global supply continuity
• Regulatory documentation under U.S., European, and other pharmacopoeias

A high-dose product with four tablets per day increases annual tablet production. Even modest market penetration can create meaningful demand for direct-compression cellulose.

Croscarmellose sodium

Croscarmellose sodium is important for disintegration. Supplier differentiation can come from swelling capacity, wicking performance, particle morphology, and low batch-to-batch variability.

Because acoramidis is delivered in a relatively large tablet dose, rapid and consistent disintegration is commercially relevant. Suppliers that provide formulation support and comparative performance data may have an advantage over commodity-only vendors.

Magnesium stearate

Magnesium stearate is a low-cost but process-critical lubricant. Excessive lubrication can reduce tablet hardness, slow disintegration, and affect dissolution. Opportunities exist for low-moisture, controlled-surface-area grades and technical services that optimize blending time and lubricant concentration.

This excipient is unlikely to create meaningful product differentiation by itself. Its value is more likely to arise through manufacturing reliability and control of dissolution performance.

Colloidal silicon dioxide

Colloidal silicon dioxide supports powder flow and may help manage a high-drug-load blend. The principal commercial variables are surface area, dispersion behavior, moisture control, and compatibility with the selected cellulose and disintegrant grades.

Suppliers may support ATTRUBY manufacturing through powder-flow studies, blend-uniformity work, and feeder-performance testing.

Film-coating materials

Polyvinyl alcohol, talc, and titanium dioxide form a conventional coating system. Coating suppliers can compete through:

• Premixed coating systems
• Lower coating weight
• Reduced process time
• Improved adhesion and abrasion resistance
• Consistent color and opacity
• Lower defect rates
• Reduced titanium dioxide content where market-specific requirements apply

A premixed film-coating system could reduce plant-side weighing and dispensing errors. It may also simplify technology transfer between manufacturing sites.

What commercial opportunities does ATTRUBY create for excipient manufacturers?

The commercial opportunity has four layers.

Direct supply to the innovator

The first opportunity is supply to the ATTRUBY manufacturer or its contract development and manufacturing partners. The highest-value materials are likely to be microcrystalline cellulose, croscarmellose sodium, and coating components because they are used at meaningful quantities and influence product performance.

Supply agreements may favor vendors with:

• Multiple manufacturing sites
• Drug Master File support
• Strong change-control systems
• Global regulatory coverage
• Low extractables and elemental-impurity risk
• Capacity for commercial-scale production

Generic development

ATTRUBY is a small-molecule product. Future competitors would generally pursue an abbreviated new drug application, or ANDA, rather than a biosimilar pathway. Generic developers will need to match the reference product’s critical quality attributes, including tablet strength, dissolution, impurities, assay, content uniformity, and stability.

Excipients that can provide comparable performance without unnecessary formulation complexity may reduce generic-development cost. Suppliers with compendial documentation, reference-grade characterization, and formulation support can benefit from multiple ANDA programs.

Contract manufacturing and technology transfer

ATTRUBY’s conventional tablet architecture is compatible with many commercial solid-dose facilities. This creates opportunities for:

• Contract development and manufacturing organizations
• High-speed tablet compression providers
• Film-coating specialists
• Packaging companies
• Analytical laboratories
• Process-validation consultants

The main technical risks are likely to involve high-dose tablet compression, blend uniformity, dissolution, coating robustness, and scale-up rather than novel delivery technology.

Lifecycle management

Potential lifecycle opportunities include:

• Lower tablet-count regimens
• Higher-strength tablets
• Improved swallowability
• Modified tablet geometry
• Patient-centric packaging
• Combination therapy packaging
• Formulations tailored to dysphagia or geriatric patients

Any lifecycle strategy would need to balance improved adherence against the commercial and regulatory burden of developing a new dosage form or strength.

What FDA regulatory issues affect ATTRUBY excipient commercialization?

FDA expectations for excipients used in ATTRUBY include identity, purity, microbial quality where applicable, residual solvents, elemental impurities, stability, supplier qualification, and manufacturing-change control.[1][2]

For a conventional immediate-release tablet, the central regulatory issues are:

1. Material equivalence. A change in excipient grade can alter flow, compression, disintegration, or dissolution.
2. Supplier changes. New manufacturing sites or synthetic routes may require comparability data and regulatory assessment.
3. Elemental impurities. Titanium dioxide, talc, mineral-derived materials, and processing equipment require appropriate risk assessment under ICH Q3D.
4. Nitrosamine and impurity control. Excipient suppliers must evaluate contamination and degradation pathways where relevant.
5. Global acceptability. Formulators may need different coating or pigment systems for specific jurisdictions.
6. Change management. Excipient changes after approval may require reporting under FDA postapproval-change requirements.

The FDA-approved label identifies the excipients but does not establish that any individual excipient is protected by a separate patent or exclusive supply arrangement.[1]

What patents protect ATTRUBY and its formulation?

ATTRUBY’s principal intellectual-property value is expected to reside in acoramidis compound, crystal-form, manufacturing, dosage, and method-of-use rights rather than in the use of standard excipients.

A conventional excipient combination such as microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, polyvinyl alcohol, talc, and titanium dioxide generally has limited standalone patent strength unless the sponsor claims a specific composition, process, dissolution profile, stability property, or clinical use.

How strong is the formulation patent estate?

The formulation estate should be assessed across five categories:

Patent category	Relevance to ATTRUBY	Generic-entry impact
Acoramidis compound claims	Protect the active pharmaceutical ingredient	Potentially high
Salt, polymorph, or crystalline-form claims	Protect the commercial active form	Potentially high
Tablet formulation claims	Protect composition or performance	Moderate to high if claims are narrow and valid
Method-of-use claims	Protect treatment of ATTR cardiomyopathy	Depends on labeling and enforceability
Manufacturing claims	Protect synthesis, purification, or crystallization	Can raise cost and technical barriers

The excipient package alone is unlikely to create a strong barrier to generic entry. Generic manufacturers may use different grades or substitute excipients if they demonstrate pharmaceutical equivalence and bioequivalence.

When could generic competition affect ATTRUBY?

ATTRUBY’s generic-entry timing will depend on listed patents, FDA-recognized regulatory exclusivities, patent litigation, and any settlement agreements. Small-molecule competitors would use the ANDA pathway and could submit Paragraph IV certifications against listed patents.

A Paragraph IV challenge would state that a listed patent is invalid, unenforceable, or not infringed. If the patent holder files suit within the statutory period, FDA approval may be subject to a 30-month stay, subject to litigation outcomes and regulatory exceptions.[3]

The relevant commercial scenarios are:

Scenario	Commercial effect
No early Paragraph IV challenge	Innovator retains a clearer period of market protection
Paragraph IV challenge without settlement	Litigation costs and possible launch uncertainty
Settlement with licensed entry date	Predictable but potentially earlier generic entry
Successful early challenge	Accelerated generic competition and price pressure
Formulation-only challenge	Limited impact if compound or method claims remain enforceable
Non-infringing alternative formulation	Greater risk to formulation patents

Because ATTRUBY is a small molecule, biosimilar risk is not applicable. The competitive threat is generic acoramidis, not a biosimilar.

What is the Orange Book status of ATTRUBY?

ATTRUBY’s Orange Book position should be evaluated through the FDA’s current publication for listed patents and exclusivity information.[3] The relevant review should identify:

• Approved product and active ingredient
• Listed patents
• Patent expiration dates
• Pediatric exclusivity, if any
• New chemical entity or other regulatory exclusivity
• Method-of-use listings
• Whether formulation patents are listed
• Whether any patent listing has been disputed

The prescribing information confirms FDA approval and the commercial dosage form, but it does not provide a complete patent-status analysis.[1] Orange Book status can change through patent-listing updates, litigation, court decisions, and regulatory exclusivity events.

How does ATTRUBY compare commercially with tafamidis?

ATTRUBY gives prescribers a second approved stabilizer for ATTR cardiomyopathy. Its commercial opportunity depends on clinical differentiation, pricing, payer access, diagnosis rates, and physician willingness to switch established tafamidis patients.

The main competitive variables are:

• Mortality and cardiovascular-hospitalization outcomes
• Tolerability
• Dosing frequency
• Tablet or capsule burden
• Formulary placement
• Prior authorization requirements
• Net price and rebate structure
• Availability for hereditary and wild-type disease
• Long-term real-world evidence

The ATTR cardiomyopathy market remains dependent on improved diagnosis. Expansion of genetic testing, nuclear scintigraphy, cardiology screening, and disease awareness can increase the treated population for both ATTRUBY and tafamidis.

What revenue exposure does ATTRUBY create for suppliers?

The largest revenue exposure is not the excipient cost per tablet. Excipients usually represent a small fraction of branded-drug revenue. The commercial value arises from recurring demand and the number of tablets required per patient.

At four tablets per day, one patient uses approximately 1,460 tablets annually. Every 10,000 treated patients therefore represent approximately 14.6 million tablets per year before accounting for wastage, titration, samples, or inventory.

That volume supports opportunities in:

• Tablet excipient supply
• Contract compression
• Coating systems
• Bottles and desiccants
• Serialization and packaging
• Stability testing
• Generic formulation development

Key Takeaways

• ATTRUBY is a conventional immediate-release, film-coated tablet containing acoramidis hydrochloride.
• The labeled excipients are microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, polyvinyl alcohol, talc, and titanium dioxide.
• The four-tablet daily regimen creates recurring demand for tablet materials and manufacturing capacity.
• The strongest excipient opportunities are in direct-compression cellulose, croscarmellose sodium, coating systems, and technical support.
• The formulation does not depend on a novel excipient or specialized drug-delivery technology.
• ATTRUBY is exposed to future ANDA-based generic competition, not biosimilar competition.
• Compound, salt, crystal-form, method-of-use, and manufacturing patents are likely to have greater strategic value than standard excipient claims.
• Orange Book patents, expiration dates, Paragraph IV challenges, litigation, and settlements require current FDA and court-record review.
• Commercial performance will depend on clinical differentiation from tafamidis, payer access, diagnosis expansion, and adherence to a four-tablet daily regimen.

FAQs

Is ATTRUBY a biologic that could face biosimilar competition?

No. ATTRUBY contains acoramidis hydrochloride, a small-molecule active ingredient. Future competitors would generally use the ANDA generic-drug pathway.

Does ATTRUBY use a patented excipient?

The FDA label identifies conventional pharmaceutical excipients but does not establish that any particular excipient is patented for ATTRUBY. The principal IP analysis should focus on acoramidis, dosage forms, methods of use, and manufacturing.

Could a generic manufacturer use different ATTRUBY excipients?

Yes. A generic manufacturer may use alternative excipients if the product satisfies applicable pharmaceutical-equivalence, bioequivalence, quality, and stability requirements.

What is the largest excipient demand driver for ATTRUBY?

Microcrystalline cellulose is likely to be the largest-volume excipient because it functions as the principal tablet diluent and compression aid. Croscarmellose sodium and coating materials are also commercially relevant.

Is a lower-pill-count ATTRUBY formulation commercially attractive?

Yes. A higher-strength tablet, altered tablet geometry, or other patient-centric dosage form could reduce pill burden. Such changes would require formulation development, stability work, regulatory review, and assessment of any applicable patent rights.

References

1. U.S. Food and Drug Administration. (2024). ATTRUBY (acoramidis) tablets: Prescribing information. FDA.

2. International Council for Harmonisation. (2022). ICH Q3D(R2): Guideline for elemental impurities. ICH.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.